SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Benjamin Franklin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBenjamin Franklin
Date of birth1706-01-17
IdentifiersMRN HR-EN004-SYN-TD; SSN (made up) 000-04-3318
Document date1782-05-18
AuthorLydia Penhallow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review four weeks after stone removal and prostate resection. [S]

History of Present Illness

Mr. Franklin returns four weeks after transurethral laser cystolitholapaxy and resection of the prostate. The catheter came out on the second day after surgery. His stream is strong, he gets up once at night, and he has had no pain or blood in the urine for two weeks. Stone analysis showed pure uric acid. He has had no gout flare on allopurinol 200 mg and colchicine. The planned urate check two to five weeks after the dose increase was not done, because his surgery fell in that window. He completed a 24-hour urine collection yesterday. He drinks about 1.5 L a day and finds it hard to drink more. Tamsulosin was stopped at surgery. [S]

ElementDetail
SurgeryCystolitholapaxy and transurethral resection four weeks ago; uncomplicated
Stone analysis100 percent uric acid
Urinary symptomsStrong stream, nocturia once, no pain or blood for two weeks
GoutNo flare on allopurinol 200 mg and colchicine
FluidsAbout 1.5 L a day
Medicines stoppedTamsulosin at surgery

Review of Systems

SystemResultFinding
GenitourinaryNegativeNo dysuria, hematuria, or incontinence; nocturia once
MusculoskeletalNegativeNo joint pain; no muscle aches on atorvastatin
ConstitutionalNegativeNo fever since surgery

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1775-05-06 to 1782-03-02stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-03-02activeS
Allopurinol 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-03-02 to 1782-03-30completedS
Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth dailyTwo tablets by mouth dailyOral route1782-03-30 to 1782-05-18completedS
Allopurinol 300 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-05-18activeS
Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxisOne tablet by mouth dailyOral route1782-03-02 to 1782-09-14completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route1782-03-02activeS
Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgeryOne capsule by mouth at bedtimeOral route1782-03-30 to 1782-04-20completedS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1782-03-30activeS
Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route1782-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1782-05-18Body height175cmS
1782-05-18Body weight94.6kgS
1782-05-18Body mass index (BMI) [Ratio]30.9kg/m2S
1782-05-18Systolic blood pressure132mm[Hg]S
1782-05-18Diastolic blood pressure78mm[Hg]S
1782-05-18Heart rate72/minS
1782-05-18Respiratory rate16/minS
1782-05-18Body temperature36.7CelS
1782-05-18Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1782-05-18Urate [Mass/volume] in Serum or Plasma6.4mg/dL3.5-7.2 mg/dLNormalS
1782-05-18Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1782-05-18Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1782-05-18Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
1782-05-18Urea nitrogen [Mass/volume] in Serum or Plasma20mg/dL8-23 mg/dLNormalS
1782-05-18Creatinine [Mass/volume] in Serum or Plasma1.31mg/dL0.74-1.35 mg/dLNormalS
1782-05-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M56mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1782-05-18Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
1782-05-18pH of Urine5.3[pH]4.5-8 [pH]NormalS
1782-05-18Erythrocytes [#/area] in Urine sediment by Microscopy high power field1/[HPF]<=2 /[HPF]NormalS
1782-05-18Volume of 24 hour Urine1.45L/(24.h)At least 2.5 L a day for stone preventionLowS
1782-05-18Urate [Mass/time] in 24 hour Urine840mg/(24.h)<=800 mg/(24.h)HighS
1782-05-18Citrate [Mass/time] in 24 hour Urine410mg/(24.h)>=320 mg/(24.h)NormalS
1782-05-18Calcium [Mass/time] in 24 hour Urine180mg/(24.h)<=250 mg/(24.h)NormalS
1782-05-18US Urinary bladder Volume post void35mL<=100 mLNormalS
1782-05-18International Prostate Symptom Score [IPSS]6{score}S

Physical Exam

Vital signs recorded on 1782-05-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell
AbdomenNo suprapubic tenderness; bladder not palpable
JointsNo synovitis or tophi
CardiovascularRegular rhythm; no edema

Problems

ProblemClinical statusVerificationCodeProvenance
Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented goutactiveconfirmed M1A.0710S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D).
Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stoneresolvedconfirmed N21.0S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known.
Chronic kidney disease stage G3a A1activeconfirmed N18.31S — Synthetic diagnosis; no measure of kidney function from his lifetime exists.
Essential hypertensionactiveconfirmed I10S — Synthetic diagnosis; no blood pressure from his lifetime exists.
Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resectionactiveconfirmed N40.1S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySerum urateEvery 2 to 5 weeks while titrating; every 6 months once at targetCompleted today6.4 mg/dL on allopurinol 200 mg; dose increased to 300 mg
LaboratorySerum urate 2 to 5 weeks after raising allopurinol to 200 mgOnce after each dose changeDeferredNot drawn in the window, a deviation from the protocol; the surgery fell in that period and the check was not rebooked. It is seven weeks today. No harm: no flare, and the dose is raised today. Corrective action: a standing urate order every four weeks until target
Medication safetyFlare prophylaxis and allopurinol tolerance3 to 6 months; every visit while titratingCompleted todayColchicine week 11; no rash or muscle symptoms
LaboratoryMetabolic evaluation after a stone: 24-hour urineOnce, within 6 months of a stone eventCompleted todayVolume 1.45 L, uric acid 840 mg/day, citrate 410 mg/day, calcium 180 mg/day
LaboratoryUrinalysis: urine pH and red cellsAfter stone treatment; with each change in alkalinizationCompleted todaypH 5.3; red cells 1 per high-power field, cleared
LaboratoryMetabolic panelWith each eGFR draw; after starting potassium-affecting therapyCompleted todayPotassium 4.5 mmol/L, creatinine 1.31 mg/dL, eGFR 56
ExaminationOffice and home blood pressureEvery visitCompleted today132/78 mmHg
SurveyIPSSEvery follow-up; 1, 3, 6, and 12 months after a procedureCompleted today6, down from 16
ExaminationPost-void residual after the procedurePost-procedural follow-upCompleted today35 mL
ImagingImaging for hematuriaOnly if hematuria persists after the stone is treatedNot indicatedHematuria cleared and cystoscopy showed no tumor
Medication safetyMedication review for NSAIDs and dose adjustmentEvery visitCompleted todayNo NSAIDs; tamsulosin stopped at surgery
Self-managementFluid intakeEvery visitCompleted todayAbout 1.5 L a day, below the goal; measuring jug advised

Goal progress:

Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026)

Follow-up: Potassium and serum urate in 2 to 5 weeks. Gout, stone, kidney, and blood pressure review in about four months. Next scheduled visit 1782-09-14: gout, stone prevention, kidney, and blood pressure review at about six months. [S]